![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Characterization of Virologic Resistance in HCV Genotype 1 Null Responders Receiving a Dual Direct- Acting Antiviral Combination of NS3 Protease Inhibitor Asunaprevir (ASV; BMS-650032) and NS5A Replication Complex Inhibitor Daclatasvir (DCV; BMS-790052) (poster presentation)
|
|
|
Reported by Jules Levin
HepDART 2011
Koloa, Hawaii, December 4-8, 2011
F McPhee, D Hernandez, F Yu, J Ueland, R Fridell, C Wang, A Monikowski, N Zhou, S Levine, D Gardiner, E Hughes, H Watanabe, H Ishikawa, H Kumada, M Gao, Bristol Myers-Squibb
![hepDart1.gif](../images/120811/120811-7/hepDart1.gif)
![hepDart2.gif](../images/120811/120811-7/hepDart2.gif)
![hepDart3.gif](../images/120811/120811-7/hepDart3.gif)
![hepDart4.gif](../images/120811/120811-7/hepDart4.gif)
![hepDart5.gif](../images/120811/120811-7/hepDart5.gif)
![hepDart6.gif](../images/120811/120811-7/hepDart6.gif)
![hepDart7.gif](../images/120811/120811-7/hepDart7.gif)
![hepDart8.gif](../images/120811/120811-7/hepDart8.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|